The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial

Meijuan Li,Ying Liu,Yuying Qiu,Jing Zhang,Yonghui Zhang,Yongping Zhao,Qiong Jia,Jie Li
DOI: https://doi.org/10.1016/j.psychres.2021.113899
IF: 11.3
2021-06-01
Psychiatry Research
Abstract:<p>Previous studies have shown that berberine can improve metabolic disturbances in non-psychiatric patients, but no clinical research has been conducted in schizophrenia. This study was a randomized, double-blind, placebo-controlled clinical trial. Eligible patients diagnosed with schizophrenia were randomized to receive placebo or berberine (900mg/day) as an adjunctive treatment for eight weeks. Peripheral glycolipid metabolism parameters were measured at baseline, week 4, and week 8. Sixty-five patients were included, and forty-nine patients completed the 8-week trial. Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all <em>p</em>&lt;0.05) compared with placebo. Baseline body mass index and serum prolactin concentration could predict the effect of berberine on insulin resistance. Berberine adjunctive treatment may reduce the risk of glycolipid metabolic disturbances in patients with schizophrenia.</p>
psychiatry
What problem does this paper attempt to address?
### Problems the Paper Attempts to Solve This paper aims to explore the effects of berberine as an adjunctive therapy on glucose and lipid metabolism in patients with schizophrenia. Specifically, the researchers hope to evaluate whether berberine can improve glucose and lipid metabolism disorders in patients with schizophrenia through a randomized, double-blind, placebo-controlled clinical trial. ### Background and Significance 1. **Metabolic Issues in Patients with Schizophrenia**: - Patients with schizophrenia often have metabolic disorders, such as metabolic syndrome (MetS), with a prevalence of about 30%, which is twice that of the general population. - Metabolic disorders can lead to decreased quality of life, high discontinuation rates, increased risk of cardiovascular diseases, and impaired cognitive function. 2. **Existing Treatment Strategies**: - Currently recommended strategies include behavioral interventions, reducing the dosage of antipsychotic drugs, switching to antipsychotic drugs with lower metabolic risk, and symptomatic treatment. - Commonly used medications include hypoglycemic drugs, statins, and antihypertensive drugs, but each additional new drug can bring new drug interactions or adverse reactions. 3. **Mechanism of Action of Berberine**: - Berberine is an isoquinoline alkaloid that has been used in China for thousands of years to treat diarrhea and gastrointestinal diseases. - In recent years, studies have shown that berberine has various pharmacological effects, including anti-inflammatory, neuroprotective, regulation of glucose and lipid metabolism, and weight loss. - In basic research, berberine has been shown to prevent glucose and lipid metabolism disorders induced by antipsychotic drugs such as olanzapine, clozapine, and risperidone. 4. **Application in Non-Psychiatric Patients**: - In non-psychiatric patients, an increasing number of studies have shown that berberine can improve metabolic disorders. - A recent meta-analysis showed that berberine, used alone or in combination with hypoglycemic drugs, significantly reduces fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes. - In the field of lipid metabolism, two recent meta-analyses reported that berberine can reduce total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-c) levels. ### Research Hypothesis Based on the above background, the researchers hypothesize that berberine can improve negative symptoms in patients with schizophrenia by regulating brain inflammation and improve metabolic disorders by regulating glucose and lipid metabolism. ### Research Design - **Trial Design**: This is an 8-week randomized, double-blind, placebo-controlled clinical trial (NCT 03548155). - **Primary Outcome**: Changes in negative symptoms. - **Secondary Outcome**: Changes in glucose and lipid metabolism parameters. ### Conclusion - **Main Findings**: - At week 8, the berberine group had significantly lower levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) compared to the placebo group. - The berberine group had significantly lower fasting serum insulin (FINS) and homeostasis model assessment of insulin resistance (HOMA-IR). - Patients with a higher baseline body mass index (BMI) and lower baseline serum prolactin concentration were more likely to benefit from berberine treatment. - **Safety**: - During the 8-week study period, there was no significant difference in the incidence of adverse events between the two groups. - The main adverse events in the berberine group included bloating, constipation, diarrhea, and sinus bradycardia, with one case withdrawing from the trial due to bloating, and the remaining adverse events were considered unrelated to berberine. ### Significance This study is the first to report the regulatory effects of berberine on glucose and lipid metabolism in patients with schizophrenia, providing a new treatment option for improving metabolic disorders in patients with schizophrenia.